Cargando…
Real‐world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower‐risk myelodysplastic syndromes
INTRODUCTION: The presence of ring sideroblasts (RS) and mutation of the SF3B1 gene are diagnostic of lower‐risk (LR) myelodysplastic syndromes (MDS) and are correlated with favorable outcomes. However, information on testing and reporting in community‐based clinical settings is scarce. This study f...
Autores principales: | Patel, Jay L., Abedi, Mehrdad, Cogle, Christopher R., Erba, Harry P., Foucar, Kathryn, Garcia‐Manero, Guillermo, Grinblatt, David L., Komrokji, Rami S., Kurtin, Sandra E., Maciejewski, Jaroslaw P., Pollyea, Daniel A., Revicki, Dennis A., Roboz, Gail J., Savona, Michael R., Scott, Bart L., Sekeres, Mikkael A., Steensma, David P., Thompson, Michael A., Dawn Flick, Elizabeth, Kiselev, Pavel, Louis, Chrystal U., Nifenecker, Melissa, Swern, Arlene S., George, Tracy I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247031/ https://www.ncbi.nlm.nih.gov/pubmed/33220019 http://dx.doi.org/10.1111/ijlh.13400 |
Ejemplares similares
-
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect(®) MDS/AML Disease Registry
por: Pollyea, Daniel A., et al.
Publicado: (2020) -
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study
por: Steensma, David P., et al.
Publicado: (2016) -
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022) -
P589: IMPLICATIONS OF REGISTRY DATA FOR ACUTE MYELOID LEUKEMIA (AML) TREATMENT AND CARE DURING THE COVID-19 PANDEMIC
por: Scott, Bart, et al.
Publicado: (2023) -
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence
por: Nazha, Aziz, et al.
Publicado: (2019)